Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Waxman letter to Kessler

Executive Summary

California Democrat tells FDA commissioner in a September letter that he is "concerned" that FDA's Aug. 28 Federal Register notice soliciting comment on the proposed withdrawal of 116 pre- 1986 pending regulations does not contain enough information. Waxman said FDA should "describe the substance" of each reg to provide for public comment and argued that "it is not appropriate to withdraw a proposed rule simply because it is more than six years old and has not been designated 'high priority.'" Instead, each proposal should be considered independently, to be pursued if it has merit and withdrawn if it does not," Waxman wrote. The move to eliminate lingering regs was initiated by new Deputy Commissioner for Policy Michael Taylor ("The Pink Sheet" Sept. 2, p. 13)....

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel